OSL Stock Overview
A medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in Australia, New Zealand, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
OncoSil Medical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.007 |
| 52 Week High | AU$0.015 |
| 52 Week Low | AU$0.004 |
| Beta | 0.94 |
| 1 Month Change | 0% |
| 3 Month Change | -41.67% |
| 1 Year Change | -22.21% |
| 3 Year Change | -83.72% |
| 5 Year Change | -95.88% |
| Change since IPO | -96.50% |
Recent News & Updates
Recent updates
Companies Like OncoSil Medical (ASX:OSL) Could Be Quite Risky
May 24
Here's Why We're Watching OncoSil Medical's (ASX:OSL) Cash Burn Situation
Feb 03Is OncoSil Medical (ASX:OSL) In A Good Position To Deliver On Growth Plans?
Oct 20OncoSil Medical (ASX:OSL) Is In A Good Position To Deliver On Growth Plans
May 13OncoSil Medical's (ASX:OSL) Stock Price Has Reduced 42% In The Past Five Years
Mar 21We're Not Worried About OncoSil Medical's (ASX:OSL) Cash Burn
Jan 26How Much Did OncoSil Medical's(ASX:OSL) Shareholders Earn From Share Price Movements Over The Last Year?
Dec 04
Shareholder Returns
| OSL | AU Life Sciences | AU Market | |
|---|---|---|---|
| 7D | 0% | 1.1% | -2.7% |
| 1Y | -22.2% | 13.9% | 6.5% |
Return vs Industry: OSL underperformed the Australian Life Sciences industry which returned 13.9% over the past year.
Return vs Market: OSL underperformed the Australian Market which returned 6.5% over the past year.
Price Volatility
| OSL volatility | |
|---|---|
| OSL Average Weekly Movement | 19.2% |
| Life Sciences Industry Average Movement | 8.9% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: OSL's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: OSL's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Nigel Lange | www.oncosil.com |
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in Australia, New Zealand, and Europe. Its lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
OncoSil Medical Limited Fundamentals Summary
| OSL fundamental statistics | |
|---|---|
| Market cap | AU$31.48m |
| Earnings (TTM) | -AU$11.91m |
| Revenue (TTM) | AU$1.57m |
20.1x
P/S Ratio-2.6x
P/E RatioIs OSL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OSL income statement (TTM) | |
|---|---|
| Revenue | AU$1.57m |
| Cost of Revenue | AU$1.51m |
| Gross Profit | AU$55.63k |
| Other Expenses | AU$11.97m |
| Earnings | -AU$11.91m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0026 |
| Gross Margin | 3.55% |
| Net Profit Margin | -761.07% |
| Debt/Equity Ratio | 0% |
How did OSL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 23:23 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
OncoSil Medical Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Thomas Duthy | Taylor Collison Limited |
| Shane Storey | Wilsons Advisory and Stockbroking Ltd. |